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Vascular invasion and lymph node metastasis have been used as histopathological prognosticators 
of cancers including oral squamous cell carcinoma (OSCC). In addition to metastatic potential 
via blood vessels, tumor-induced angiogenesis might also be associated with prognosis. However, 
the efficacy of combined evaluation of vascular invasion and angiogenesis-associated molecules 
for the prognosis of OSCC remains obscure. This is also the case in lymph node metastasis and 
lymphovasculogenesis-associated molecules. The aim of this study was to examine factors 
related to prognosis to improve the accuracy of prognostic prediction of OSCC using 
vasculogenesis-associated markers. Ninety specimens of patients from 1991 to 2002 with 
previously untreated OSCC, who underwent either biopsy or surgery, were histopathologically 
and immunohistochemically analyzed using antibodies for vascular endothelial growth factor 
(VEGF)-A, VEGF-C, cyclooxygenase (COX)-2 and Midkine. The ninety cases were composed 
of 72 well-differentiated, 12 moderately differentiated and 6 poorly differentiated OSCC. 
Efficient models of prognostic prediction were evaluated by extensive statistical analyses. The 
presence of vascular invasion or lymph node metastasis was confirmed to be significantly 
associated with poor prognosis in the univariate analysis. Multivariate logic regression analysis 
suggested that patients with the strongly positive expression of either VEGF-A or VEGF-C had a 
significant association with poor prognosis even in patients without vascular invasion and in 
early-stage patients. Neither COX-2 nor Midkine contributed to predict the prognosis of the 
patients. The strongly positive expression of VEGF-A or VEGF-C was suggested to reinforce the 
histopathological diagnosis of vascular invasion and improve the accuracy and efficacy of 
prognostic prediction of OSCC. 
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The incidence of oral squamous cell carcinoma (OSCC) is relatively high and it has been reported 
to be the eighth most common cancer worldwide.1, 2 In addition, increasing incidence of OSCC is 
observed more in Europe, Japan, and in the younger generation in many western countries.3 
Despite advances in clinical treatments, survival rates of OSCC have not improved for 
decades.4 It is considered particularly important to find and treat OSCC at an early stage. In the 
oral cavity, OSCC is most frequently seen in the posterior-lateral border of the tongue.1, 5 
VEGF-A, which was discovered as a factor that induces capillary and endothelial cell growth, 
was also recognized to be associated with tumor-induced angiogenesis.6 VEGF-C, one of the 
other members of the VEGF family, was found to be preferentially associated with tumor-induced 
lymphovasculogenesis.7, 8 
COX-2 is a well-known enzyme that metabolizes arachidonic acid and induces cell membrane 
phospholipid-derived inflammation. Close association of the expression of COX-2 with 
carcinogenesis and tumor-induced angiogenesis has begun to be elucidated9-11 and the expression 
of COX-2 has been identified as a possible marker to recognize carcinogenesis.12 
MK, which was initially found as a molecule expressed in embryonal carcinoma cells, has 
been shown to promote the growth, survival and migration of various cells, including endothelial 
cells, and has also been shown to be involved in the regulation of epithelial–mesenchymal 
interactions.13 In addition, the expression of MK was found to be increased in various human 
tumors,13-15 and has also been suggested to promote or modulate angiogenesis.16-18 
Including the tongue, most of the oral cavity is visible, and it is considered advantageous for 
early discovery of cancer, but proper medical knowledge and good medical as well as dental care 
systems are essential. In the hospital, histopathological diagnosis of the lesion is required to 
determine the course of treatment. Histopathological diagnosis of operation specimens has 
additionally been desired to provide information to predict prognosis in concert with clinical and 
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imaging data based on tumor-node-metastasis (TNM) classification of tumors. However, further 
clinically applicable highly efficient prognosticators of OSCC have not been approved, although 
many possible candidates could be introduced. In this study, an attempt was made to improve one 
of the reliable histopathological prognosticators for vascular invasion using multiple 
vasculogenesis-associated factors, VEGF-A, VEGF-C, COX-2 and MK. 
 
Materials and methods 
Patients and materials 
Ninety specimens of patients with previously untreated OSCC, who underwent either biopsy or 
surgery with or without preoperative treatment, were included. Patients were admitted to the 
Second Department of Oral and Maxillofacial Surgery, Nagasaki University Dental Hospital, 
from 1991 to 2002. They were composed of 58 male and 32 female patients ranging from 31 to 
87 years of age with a mean age of 65.4 years. Forty-eight patients were treated with a standard 
program of preoperative irradiation of Linac at a total of 30 Gy and preoperative continuous 
subcutaneous administration of peplomycin (5 mg / day; maximum dosage, 100 mg). Nine 
patients were treated only with the preoperative irradiation, 12 patients were treated only with the 
preoperative administration of peplomycin and 21 patients were untreated before surgery. In 
histopathological diagnosis, 72 cases were well-differentiated, 12 cases were moderately 
differentiated and 6 cases were poorly differentiated OSCCs. All the patients were followed at the 
hospital until 2005. Among them, 66 patients (73.3%) died and 24 patients (26.7%) survived 
during the follow-up period. This study was approved by the ethics committee of the Nagasaki 
University Graduate School of Biomedical Sciences. 
 
Histopathological analyses 
Specimens were routinely processed with a 10% buffered formalin fixative and embedded in 
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paraffin. Morphology of tumor cells was evaluated using specimens stained with hematoxylin 
and eosin, and the presence of vascular invasion (v-factor) was evaluated using specimens stained 
with the method of Elastica van Gieson (EVG). Antibodies for vascular endothelial growth factor 
(VEGF)-A, VEGF-C (both from Zymed Laboratories Invitogen Immunodetection, San Francisco, 
CA), cyclooxygenase (COX)-2 (Cayman Chemical, Ann Arbor, MI) and Midkine (MK) (Yamasa, 
Chiba, Japan) were used. Sections were pretreated with an autoclave at 121 oC for 15 minutes in 
10 mM citrate buffer (pH 6.0) to activate antigens, incubated with each antibody described above 
at x100 dilution with PBS at 4 oC overnight and immunohistochemical analysis was carried out 
on the EnVision+ System (Dako, Carpinteria, CA). 
  The expression of VEGF-A, VEGF-C and COX-2 was graded according to the percentage score 
of the stained carcinoma cells as follows: no expression (code 0), weakly positive expression (code 
1) where less than 25% were positive carcinoma cells, moderately positive expression (code 2) 
where more than 25% to less than 50% were positive carcinoma cells and strongly positive 
expression (code 3) where more than 50% were positive carcinoma cells under magnifications of 
100x and 200x. Owing to the general low intensity of MK immunoreactivity, the expression was 
ranged from no expression (code 0), weak expression (code 1), which was defined as less than 50% 
being positive carcinoma cells, to firm expression (code 2), in which more than 50% were positive 
carcinoma cells. Because VEGF-A, VEGF-C, COX-2 and MK were dominantly localized in the 
cytoplasm of expressing cells, chromogenic reactivity in the nucleus was omitted for evaluation of 
positivity. 
  Positive controls for these immunoreactions were taken using normal human liver specimens 
derived from autopsy cases, and negative controls were taken using specimens reacted with 





Cox proportional hazards regression models were used to identify the prognostic factors. 
Prognosis status was defined for patients that died during the observation period as poor and for 
patients that were alive as good. Survival time was defined as the time interval between the date 
of the first surgical operation and the date of death from any cause, or censoring based on the date 
of last contact. In univariate analyses, we used indicator variables for the factors with more than 
two ordered categories, such as age group or stage of tumor. Significant factors from univariate 
analyses were examined by multivariate analyses to select a set of factors that show better fit to 
the data, from a combination of prognostic factors. For the model selection, we used Akaike’s 
Information Criterion (AIC).19 For the parameterization of factors in each regression model, we 
used linear combinations of covariates, which are usually used in clinical epidemiology, and also 
used logic combinations of prognostic factors. The estimated relative risks (RRs) by the selected 
factors were calculated using estimated regression coefficients of the best model to predict. 
Survival curves were calculated by the Kaplan–Meier method and then compared by the log-rank 
test. Statistical procedures were performed with the Statistical Language R.20  P-values <0.05 




VEGF-A-positive tumor cells were detected in all the analyzed specimens and the expression in 
tumor cells ranged from codes 1 to 3. VEGF-A expression was also detected in vascular 
endothelial cells, which were omitted for evaluation of positivity using the morphological 
differences of tumor cells from vascular endothelial cells in serial sections stained with 
hematoxylin and eosin. The expression of VEGF-C and COX-2 ranged from codes 0 to 3. The 
expression of MK ranged from codes 0 to 2. Representative cases of each grade for VEGF-A and 
VEGF-C expression are shown in Fig. 1. Fifty-four cases had no vascular invasion and 33 cases 
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were positively recognized. The remaining three cases, which were two well-differentiated and 
one poorly differentiated OSCCs, were omitted from the analyses because of the false positive 
reaction in negative control sections. 
 
Univariate and multivariate analyses 
Study subjects by factors related to prognosis (risk factors) and their estimated RRs for poor 
prognosis based on Cox regressions are listed in Table 1. We observed that v-factor, the 
expression of VEGF-A, the expression of VEGF-C and T, N and clinical stage (Stage) of TNM 
classification were statistically significant. For example, the estimated RR for poor prognosis of 
subjects with code 1 to that of code 0 of v-factor was 3.994 (p <0.0001). (See the Table 1 for the 
other significant variables.) Sex, age, MK and COX-2 were not significant, but the estimated RR 
for poor prognosis of subjects more than 70 years old to that of those less than 50 years old was 
2.012 (p = 0.097). As differences between 10-year age groups were not statistically significant 
but suggestive, we pooled subjects less than 70 years old, and obtained a value of p < 0.0001 
(data not shown); then, we used two groups with a cut-off point of 70 years old in multivariate 
analysis. Similarly, it was suggested to pool subjects with codes 1 and 2 of VEGF-A, codes 0, 1 
and 2 of VEGF-C, Stages I and II as well as Stages III and IV, T-stages 1 and 2 as well as T-stages 
3 and 4, N-stages 0 and 1 as well as N-stages 2 and 3 and use each of them for multivariate 
analysis. 
Multivariate analysis revealed that the Cox proportional hazards model with covariates of age 
groups, stages and a logical combination of covariates of v-factor, VEGF-A and VEGF-C had 
smaller AIC values than any other model with a linear combination of covariates (Table 2). In this 
selected model 1, the logical combination of covariates (we call them “important prognosis 
factors” (IPF)) had the value of zero when v-factors equaled 0, VEGF-A was less than 3 and 
VEGF-C was less than 3, and had the value of one otherwise, and the “IPF” was strongly 
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significant (p <0.0001). When T and N stages were used instead of clinical stage (I - IV) in 
selected model 1, better fitted model 2 with smaller AIC value was obtained. It should be noted 
that VEGF-A and VEGF-C were not statistically significant in linear combination model 1, which 
has been used widely in clinical epidemiology. Therefore, this result of model 1 led to the form of 
linear combination model 2 without VEGF-A and VEGF-C factors. However, AIC value of linear 
combination model 2 was higher than those of logic models 1 and 2 (Table 2). 
Both logic model 1 with a clinical-stage covariate and logic model 2 with T- and N-stage 
covariates had small AIC values, and logic model 1 with a single covariate was used to 
demonstrate the importance of IPF in simple illustrations. The estimated RR for poor prognosis 
by age group, stage and IPF status is shown in Fig. 2. In the age group of less than 70 years old, 
the estimated RRs for poor prognosis of subjects with IPF = 1 in the Stage I and II group and the 
Stage III and IV group were 4.06 and 10.08, respectively. In the age group of more than 70 years 
old, RRs for poor prognosis of subjects with IPF = 1 in the Stage I and II group and the Stage III 
and IV group were 7.01 and 20.56, respectively. Estimated survival curves by stage, and by stage 
and IPF status are also shown in Fig. 3. Survival of subjects with IPF = 1 in the Stage I and II 
group was as low as that of subjects in Stage III and Stage IV (Fig. 3a and b). Estimated survival 
curves for Stage I or II and IPF status are shown in Fig. 3c. 
 
Discussion 
A large number of molecules have been reported to correlate with poor prognosis of head and 
neck squamous cell carcinomas including OSCC using cell biological analyses.4 However, most 
of these molecules have not been routinely used as diagnostic markers for the prediction of 
prognosis in clinico-pathological laboratories. One of the reasons for this is that, except for 
differentiation markers or molecules involved in carcinogenesis, the prognostic value of these 
molecules might not be accurate enough for them to be used. 
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The expression of VEGF-A in OSCC has been analyzed and was suggested to be associated 
with the prognosis of patients, although conflicting reports have been published and the value of 
its expression for OSCC prognosis remains obscure.21-26 The association of the expression of 
VEGF-C with lymph node metastasis has been suggested, however the prognostic value of its 
expression in OSCC has not been clarified.27-29  
The estimated RR of the strongly positive expression of VEGF-A for poor prognosis based on 
Cox regression was significantly higher than that of the weakly positive expression. Hence, these 
results suggested that expression of VEGF-A itself has the potential to predict prognosis of 
OSCC; this was also the case in VEGF-C. In support of the current findings, Uehara et al. 
published a report showing that the expression of VEGF-A was significantly higher in patients 
with poor prognosis than in those with good prognosis for some of the specimens used in the 
present study.30  
Then, effective combination models using vascular invasion and the expression profile of 
markers associated with vasculogenesis were examined, and IPF was developed; the logical 
combination of covariates, which has the value of zero when v-factors equal 0, VEGF-A is less 
than 3 as well as VEGF-C is less than 3, has the value of one otherwise. It was found that IPF had 
significant prognostic value of OSCC. 
Furthermore, it was detected that two groups with a cut-off point of 70 years old significantly 
correlated with the prognosis of OSCC. Some studies demonstrated that the prognosis of older 
patients was poorer than that of younger patients, although the correlation of age with prognosis 
of OSCC is controversial.2 The explanation of poorer prognosis of patients who were more than 
70 years old than that of those less than 70 years old may be partly caused by age-matched 
reduction of immunocompetence and there is no doubt that this can be detected more easily in a 
society with much longevity like Japan. 
Interestingly, the selected model IPF revealed the highest estimated RR for poor prognosis (RR 
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= 20.56) in subjects of IPF = 1 of the Stage III and IV group, and that in subjects of IPF = 1 of the 
Stage I and II group, and more than 70 years old, was also high (RR = 7.01) when the estimated 
RR for poor prognosis of IPF = 0, Stage I and II and less than 70 years old was settled at one (Fig. 
2). These data suggested that IPF improved the accuracy of prognostic prediction of OSCC when 
used with age groups with a cut-off point of 70 years, and also suggested that IPF was associated 
with survival of OSCC patients in any stage including Stages I and II. 
Performance of IPF was confirmed by survival curves by the Kaplan–Meier method. It was 
striking that the survival curve of IPF = 1 subjects in the Stage I and II group was as low as those 
of Stage III and Stage IV subjects (Fig. 3). These data show that IPF contributes to predict 
survival of OSCC patients in early stages. 
Among 90 cases, 73% of patients died. The high mortality was thought to be associated with 
the high proportion of patients in advanced stages. Recently, many more patients in earlier stages 
have been admitted to hospital and this could greatly improve the mortality of patients with 
OSCC. This means that the prognostic prediction of patients in an early stage of OSCC is very 
important, and IPF may contribute to the choice of a course of treatment for these patients. 
In conclusion, it was demonstrated that IPF, a logic regression model using vascular invasion 
and the strongly positive expression of either VEGF-A or VEGF-C, was an effective prognostic 
predictor of OSCC not only in advanced stages, but also in early stages. Our IPF model is 
strongly expected to be applied to OSCC cases in many other institutions. 
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Figure 1: Representative expression profiles of VEGF-A and VEGF-C in 
immunohistochemical analysis 
(0), (1), (2) and (3) represent code 0 (no expression), code 1 (less than 25% of positive carcinoma 
cells), code 2 (more than 25% to less than 50% of positive carcinoma cells) and code 3 (more 
than 50% of positive carcinoma cells) of immunohistochemical grading of VEGF-A and VEGF-C. 
There was no case of code 0 for the expression of VEGF-A. 
 
Figure 2: The estimated relative risks (RRs) of subjects evaluated with IPF and stage in 
each group with a cut off point of 70 years old 
Subjects of Stages I and II (Stage I, II), and Stages III and IV (Stage III, IV) were pooled and 
analyzed. Definition of IPF was described as follows. 
IPF=0, when v=0 and VEGF-A<3 and VEGF-C<3. 
IPF=1, when v=1 or (v=0 and (VEGF-A=3 or VEGF-C=3)). 
 
Figure 3: Kaplan-Meier curves of overall survival 
(a) Curves of patients in each stage of OSCC. (b) Curves of patients evaluated with IPF in the 
Stage I and II group and the Stage III and IV group. (c) Curves of patients evaluated with IPF in 
Stage I and Stage II. 
Table 1:  Study subjects by factors and their estimated relative risk (RR) 
 
Factor  Category  Sample size Prognosis   Cox Regression 
 
Good Poor  RR p-value 
Sex  male  58  16 42  1.000 - 
  female  32   8 24  0.925 0.76 
 
Age  -49   9   2  7  1.000 - 
50-59  18   8 10  0.566 0.250 
  60-69  28  11 17  0.801 0.623 
  70-  35   3 32  2.012 0.097 
   
MK  0  55  14 41  1.000 - 
 1   3   3  0  - - 
  2  32   7 25  0.956 0.859* 
 
COX-2  0  16   7  9  1.000 - 
  1  23   4 19  1.897 0.115 
  2  25   6 19  1.869 0.124 
  3  26   7 19  1.781 0.155 
 
v-factor    0  54  23 31  1.000 - 
1             33   1 32  3.994 <0.0001 
 
 
VEGF-A  1  16      7       9       1.000 - 
  2  39    14 25       1.411 0.379 
  3  31      3 28       3.095 0.004 
 
VEGF-C  0  38     15    23       1.000 - 
  1  29       6    23       2.042 0.017 
  2  13       2    11       2.043 0.055 
  3   7       0       7       2.218 0.067 
 
Stage  Ⅰ  15       8      7      1.000 - 
  Ⅱ  17       7    10      1.817 0.248 
  Ⅲ  10       2     8      3.486 0.022 
  Ⅳ  42       5    37      4.773 0.0005 
 
T-stage  1  16       9      7      1.000 - 
  2  31      10    21      2.653 0.036 
  3   7       1     6      6.985 0.001 
  4  33       3    30      5.574 <0.0001 
 
N-stage  0  41      16     25      1.000 - 
  1  16       3    13      2.010 0.045 
  2  29       4    25      3.094 0.002 
  3   1       0     1      15.28 0.010 
 
 
Meta  0  86    23 63  1.000 - 
1   1   0  1  3.212 0.253 
 
 
*: Category 2 for MK was pooled with category 1. 
Table 2:  Results of Cox proportional hazards regression models 
 
                                        95% Confidence Interval 
Covariate   Estimated S.E.   p-value       RR      lower upper  AIC 
    Coefficients 
Selected logic model 1 (N=74) 
Age     0.642  0.29   0.028       1.90     1.07 3.37  354.4 
Stage     0.980  0.32   0.002       2.66     1.42 4.99 
IPF*     1.401  0.33  <0.0001       4.06     2.13 7.73 
 
Selected logic model 2 (N=74) 
Age     0.761  0.29   0.008       2.14     1.22 3.77  351.3 
T-stage     0.782  0.30   0.010       2.19     1.20 3.96 
N-stage      0.705  0.32   0.027       2.02     1.08 3.78 
IPF*     1.574  0.34  <0.0001       4.83     2.48 9.41 
 
Linear combination model 1  (N=74) 
Age     0.671  0.30   0.026       1.957    1.08 3.54  369.2 
Stage     0.725  0.35   0.040        2.065    1.03 4.13 
v-factor     0.834  0.38   0.031        2.302    1.08 4.90 
VEGF-A     0.217  0.37   0.561        1.242    0.60 2.58 
VEGF-C     0.298  0.42   0.481        1.347    0.59 3.08 
 
Linear combination model 2 (N=74) 
Age     0.726  0.30   0.014       2.066    1.16 3.69  366.1 
Stage     0.740  0.34   0.030        2.095    1.07 4.09 




*Note: The N means the number of subjects used in the model. 
Age=0, when age of a patient < 70.  Age=1, when age of a patient ≧70. 
         Stage=0, when a patient is in stage I or II.   Stage=1, when a patient is in stage III or IV. 
         T-stage=0, when a patient is in stage 1 or 2.  T-stage=1, when a patient is in stage 3 or 4. 
N-stage=0, when a patient is in stage 0 or 1.  N-stage=1, when a patient is in stage 2 or 3. 
IPF: important prognosis factors 
IPF=0, when v=0 and VEGF-A<3 and VEGF-C<3 
IPF=1, when v=1 or (v=0 and (VEGF-A=3 or VEGF-C=3)) 
(0) (1) (2) (3)
VEGF-A
VEGF-C
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